ETF Holdings Breakdown of ARWR

News associated with ARWR

Voya Investment Management LLC Sells 246,573 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Voya Investment Management LLC trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 82.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 53,793 shares of the biotechnology company’s stock after selling 246,573 shares during the period. Voya Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,011,000 as of its […] - 2025-05-07 08:57:00

Bank of Montreal Can Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Bank of Montreal Can grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,018 shares of the biotechnology company’s stock after purchasing an additional 1,759 shares […] - 2025-04-25 07:36:52

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $41.44 Consensus Target Price from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year […] - 2025-04-24 05:28:50

Arrowhead Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 7,512 put options on the stock. This is an increase of approximately 1,016% compared to the typical daily volume of 673 put options. Analyst Upgrades and Downgrades A number of analysts recently issued reports on the company. […] - 2025-04-23 05:50:52

Legal & General Group Plc Cuts Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Legal & General Group Plc reduced its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 3.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 245,272 shares of the biotechnology company’s stock after selling 9,369 shares during the […] - 2025-04-22 07:47:17

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 41.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 183,289 shares of the biotechnology company’s stock after selling 132,084 shares during the quarter. Russell Investments Group Ltd.’s […] - 2025-04-17 08:54:50

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stake Cut by Fmr LLC

Fmr LLC decreased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 15.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,101,083 shares of the biotechnology company’s stock after selling 966,486 shares during the period. Fmr […] - 2025-04-16 07:34:56

Geode Capital Management LLC Sells 9,172 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Geode Capital Management LLC lessened its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 0.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,954,947 shares of the biotechnology company’s stock after selling 9,172 shares during the period. Geode Capital Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $55,566,000 as […] - 2025-04-14 08:43:00

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 1.2% during the 4th quarter, HoldingsChannel reports. The fund owned 206,070 shares of the biotechnology company’s stock after selling 2,490 shares during the quarter. Schroder Investment Management Group’s holdings in Arrowhead Pharmaceuticals were worth $3,835,000 as of its most […] - 2025-04-06 09:32:58

Corebridge Financial Inc. Sells 10,761 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Corebridge Financial Inc. lowered its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 199,154 shares of the biotechnology company’s stock after selling 10,761 shares during the period. Corebridge […] - 2025-03-31 08:22:49

11,172 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Purchased by Cibc World Markets Corp

Cibc World Markets Corp acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,172 shares of the biotechnology company’s stock, valued at approximately $210,000. Several other institutional investors have also […] - 2025-03-27 08:54:57

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average […] - 2025-03-27 06:38:50

Swiss National Bank Has $4.14 Million Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Swiss National Bank grew its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 220,000 shares of the biotechnology company’s stock after buying an additional 1,700 shares during the quarter. Swiss […] - 2025-03-26 07:44:45

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stake Cut by US Bancorp DE

US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 34,522 shares of the biotechnology company’s stock after selling 5,601 shares during the period. US Bancorp DE’s holdings in Arrowhead Pharmaceuticals were worth $649,000 as of its most […] - 2025-03-12 08:43:02

Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $41.44

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price […] - 2025-03-05 06:20:53

Rhumbline Advisers Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Rhumbline Advisers raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 380,344 shares of the biotechnology company’s stock after buying an additional 7,912 shares during the period. Rhumbline […] - 2025-02-26 08:19:02

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $42.00 price target on the biotechnology company’s stock. A number of other brokerages also recently issued reports on ARWR. StockNews.com upgraded Arrowhead Pharmaceuticals to […] - 2025-02-12 09:14:54

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down Following Weak Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report)’s share price gapped down before the market opened on Tuesday following a weaker than expected earnings announcement. The stock had previously closed at $19.92, but opened at $18.23. Arrowhead Pharmaceuticals shares last traded at $19.18, with a volume of 183,105 shares. The biotechnology company reported ($1.39) earnings […] - 2025-02-12 06:36:56

2,020 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Purchased by R Squared Ltd

R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 2,020 shares of the biotechnology company’s stock, valued at approximately $38,000. A number of other institutional investors have also […] - 2025-02-03 08:47:08

ARWR institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	73,478	USD 973,584
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	49,502	USD 655,902
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	60,809	USD 805,719
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	60,809	USD 805,719
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,009	USD 13,369
Total =		245,607	USD 3,254,293

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer